Skip to main content
Clinical Trials/ACTRN12621001102864
ACTRN12621001102864
Recruiting
Phase 2

Dapagliflozin in Patients with Type-2 Diabetes Admitted to Intensive Care: A Pilot Single-Centre, Feasibility Randomised Controlled Trial

Austin Health0 sites40 target enrollmentAugust 18, 2021

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Diabetes
Sponsor
Austin Health
Enrollment
40
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 18, 2021
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Adult aged 18 years or greater
  • Expected to be admitted to the ICU until the day after tomorrow
  • Pre\-existing diagnosis of Type\-2 diabetes mellitus
  • Estimated Glomerular Filtration rate (eGFR) of less than 45 ml/min/1\.73m2
  • Able to take medication enterically

Exclusion Criteria

  • Diagnosis of Type\-1 diabetes mellitus (T1DM)
  • Documented SGLT2 inhibitor intolerance
  • Hepatic impairment with aspartate transaminase \[AST] or alanine transaminase \[ALT] greater than 3x the upper limit of normal \[ULN]; or total bilirubin greater than 2x ULN at time of enrolment
  • No enteric route for medication administration
  • Death is deemed to be imminent or inevitable during this admission
  • Patients with diabetic ketoacidosis
  • Pre\-existing urinary tract infection
  • Hypernatraemia defined as a serum sodium levels equal to or greater than 150 mmol/L at the time of screening
  • Clinician deems enrolment in the study is not in the patient’s best interests

Outcomes

Primary Outcomes

Not specified

Similar Trials